glp 1 alzheimer's disease GLP-1 drugs failed to slow in two big clinical trials ๐งWill GLP-1RA drugs be the
Description
No stimulants
GLP-1 lawsuits involve allegations that manufacturers of medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and related drugs failed to adequately warn consumers and prescribing physicians about serious health risks associated with these medications
Side effects are possible but tend to be milder with microdosing compared to higher doses
In most cases, there is no reason to discontinue GLP-1 treatment unless another specific medical indication arises
